Clinical trials are currently underway for 177Lu-PSMA-617, including an open-label randomized controlled trial for patients with metastatic hormone-sensitive prostate cancer (NCT04720157) and a phase II trial for castration-sensitive prostate cancer with oligo metastases (NCT04443062, NCT05079698), and the indication is expected to expand. The gene discussed is FOLH1; the disease is prostate cancer.